CSBio CSBio

X
[{"orgOrder":0,"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec\u2019s INS-3001 Reduces Cardiovascular Calcification","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inositec AG"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Announces Funding from Swiss Innovation Agency Supporting Research Collaborations for Long Non-Coding RNA Therapies","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"HAYA Therapeutics"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"HAYA Therapeutics Completes CHF 18 Million Seed Financing To Advance Anti-fibrotic Therapies Targeting Long Non-coding RNAs","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"HAYA Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The first project will advance lead HTX-001, an antisense oligonucleotide targeting lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart and second project will aim to develop a next-generation oncology therapy targeting cancer-associated fibroblast.

            Lead Product(s): HTX-001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HTX-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innosuisse

            Deal Size: $3.3 million Upfront Cash: Undisclosed

            Deal Type: Funding May 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics HTX-001, that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.

            Lead Product(s): HTX-001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: HTX-001

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Broadview Ventures

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Financing May 20, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.

            Lead Product(s): INS-3001

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY